{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:28:10Z","timestamp":1786980490338,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100012543","name":"Shanghai Science and Technology Development Foundation","doi-asserted-by":"publisher","award":["21ZR1438800"],"award-info":[{"award-number":["21ZR1438800"]}],"id":[{"id":"10.13039\/100012543","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Talents Development","award":["2019092"],"award-info":[{"award-number":["2019092"]}]},{"name":"Shanghai Pujiang Young Rheumatologists Training Program","award":["SPROG201907"],"award-info":[{"award-number":["SPROG201907"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s10067-022-06184-1","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T07:29:34Z","timestamp":1653031774000},"page":"2817-2823","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Short-term, low-dose etoposide in refractory adult-onset Still\u2019s disease-associated macrophage activation syndrome"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7857-8433","authenticated-orcid":false,"given":"Ran","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangjin","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-de","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5873-6422","authenticated-orcid":false,"given":"Qiong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,19]]},"reference":[{"issue":"5\u20136","key":"6184_CR1","first-page":"708","volume":"13","author":"F Balderas","year":"2014","unstructured":"Balderas F, Casillas R, Saavedra E et al (2014) Adult-onset Still\u2019s disease. Best Pract Res Clin Rheumatol 13(5\u20136):708\u2013722","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"7","key":"6184_CR2","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.autrev.2014.01.058","volume":"13","author":"M Gerfaud-Valentin","year":"2014","unstructured":"Gerfaud-Valentin M, Jamilloux Y, Iwaz J et al (2014) Adult-onset Still\u2019s disease. Autoimmun Rev 13(7):708\u2013722. https:\/\/doi.org\/10.1016\/j.autrev.2014.01.058","journal-title":"Autoimmun Rev"},{"issue":"30","key":"6184_CR3","doi-asserted-by":"publisher","first-page":"e4258","DOI":"10.1097\/MD.0000000000004258","volume":"95","author":"M Gerfaud-Valentin","year":"2016","unstructured":"Gerfaud-Valentin M, Cottin V, Jamilloux Y et al (2016) Parenchymal lung involvement in adult-onset Still disease: a STROBE-compliant case series and literature review. Medicine 95(30):e4258. https:\/\/doi.org\/10.1097\/MD.0000000000004258","journal-title":"Medicine"},{"key":"6184_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.rmcr.2017.07.001","volume":"22","author":"A Guerrieri","year":"2017","unstructured":"Guerrieri A, Angeletti G, Mazzolini M et al (2017) Pulmonary involvement in adult Still\u2019s disease: case report and brief review of literature. Respir Med Case Rep 22:91\u201394. https:\/\/doi.org\/10.1016\/j.rmcr.2017.07.001","journal-title":"Respir Med Case Rep"},{"key":"6184_CR5","doi-asserted-by":"crossref","unstructured":"Karki R, Kanneganti TD (2021) The \u2018cytokine storm\u2019: molecular mechanisms and therapeutic prospects. Trends Immunol 42(8)","DOI":"10.1016\/j.it.2021.06.001"},{"issue":"1","key":"6184_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12969-016-0130-4","volume":"15","author":"C Bracaglia","year":"2017","unstructured":"Bracaglia C, Prencipe G, De Benedetti F (2017) Macrophage activation syndrome: different mechanisms leading to a one clinical syndrome. Pediatr Rheumatol Online J 15(1):5. https:\/\/doi.org\/10.1186\/s12969-016-0130-4","journal-title":"Pediatr Rheumatol Online J"},{"issue":"2","key":"6184_CR7","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.berh.2014.03.002[publishedOnlineFirst:2014\/06\/30]","volume":"28","author":"GS Schulert","year":"2014","unstructured":"Schulert GS, Grom AA (2014) Macrophage activation syndrome and cytokine-directed therapies. Best Pract Res Clin Rheumatol 28(2):277\u2013292. https:\/\/doi.org\/10.1016\/j.berh.2014.03.002[publishedOnlineFirst:2014\/06\/30]","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"8","key":"6184_CR8","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1002\/art.38672","volume":"66","author":"S Kumakura","year":"2014","unstructured":"Kumakura S, Murakawa Y (2014) Clinical characteristics and treatment outcomes of autoimmune-associated hemophagocytic syndrome in adults. Arthritis Rheumatol 66(8):2297\u20132307. https:\/\/doi.org\/10.1002\/art.38672","journal-title":"Arthritis Rheumatol"},{"key":"6184_CR9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1146\/annurev-med-061813-012806","volume":"66","author":"GS Schulert","year":"2015","unstructured":"Schulert GS, Grom AA (2015) Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies. Annu Rev Med 66:145\u2013159. https:\/\/doi.org\/10.1146\/annurev-med-061813-012806","journal-title":"Annu Rev Med"},{"key":"6184_CR10","doi-asserted-by":"publisher","first-page":"3717392","DOI":"10.1155\/2016\/3717392","volume":"2016","author":"A Kumar","year":"2016","unstructured":"Kumar A, Kato H (2016) Macrophage activation syndrome associated with adult-onset Still\u2019s disease successfully treated with anakinra. Case Rep Rheumatol 2016:3717392. https:\/\/doi.org\/10.1155\/2016\/3717392","journal-title":"Case Rep Rheumatol"},{"key":"6184_CR11","doi-asserted-by":"publisher","first-page":"5656320","DOI":"10.1155\/2016\/5656320","volume":"2016","author":"E Watanabe","year":"2016","unstructured":"Watanabe E, Sugawara H, Yamashita T et al (2016) Successful tocilizumab therapy for macrophage activation syndrome associated with adult-onset Still\u2019s disease: a case-based review. Case Rep Med 2016:5656320. https:\/\/doi.org\/10.1155\/2016\/5656320","journal-title":"Case Rep Med"},{"key":"6184_CR12","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2147\/TCRM.S195538[publishedOnlineFirst:2021\/04\/24]","volume":"17","author":"H Yildiz","year":"2021","unstructured":"Yildiz H, Bailly S, Van Den Neste E et al (2021) Clinical Management of relapsed\/refractory hemophagocytic lymphohistiocytosis in adult patients: a review of current strategies and emerging therapies. Ther Clin Risk Manag 17:293\u2013304. https:\/\/doi.org\/10.2147\/TCRM.S195538[publishedOnlineFirst:2021\/04\/24]","journal-title":"Ther Clin Risk Manag"},{"issue":"21","key":"6184_CR13","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1182\/blood.2019002289[publishedOnlineFirst:2019\/09\/21]","volume":"134","author":"M Vallurupalli","year":"2019","unstructured":"Vallurupalli M, Berliner N (2019) Emapalumab for the treatment of relapsed\/refractory hemophagocytic lymphohistiocytosis. Blood 134(21):1783\u20131786. https:\/\/doi.org\/10.1182\/blood.2019002289[publishedOnlineFirst:2019\/09\/21]","journal-title":"Blood"},{"issue":"12","key":"6184_CR14","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1136\/annrheumdis-2018-213920[publishedOnlineFirst:2018\/10\/04]","volume":"77","author":"Y Kaneko","year":"2018","unstructured":"Kaneko Y, Kameda H, Ikeda K et al (2018) Tocilizumab in patients with adult-onset Still\u2019s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. Ann Rheum Dis 77(12):1720\u20131729. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213920[publishedOnlineFirst:2018\/10\/04]","journal-title":"Ann Rheum Dis"},{"key":"6184_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30156-5[publishedOnlineFirst:2019\/09\/21]","author":"A Ahmed","year":"2019","unstructured":"Ahmed A, Merrill SA, Alsawah F et al (2019) Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. Lancet Haematol. https:\/\/doi.org\/10.1016\/S2352-3026(19)30156-5[publishedOnlineFirst:2019\/09\/21]","journal-title":"Lancet Haematol"},{"issue":"5","key":"6184_CR16","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.jaip.2018.05.031[publishedOnlineFirst:2018\/09\/12]","volume":"6","author":"S Ehl","year":"2018","unstructured":"Ehl S, Astigarraga I, von Bahr GT et al (2018) Recommendations for the use of etoposide-based therapy and bone marrow transplantation for the treatment of HLH: consensus statements by the HLH Steering Committee of the Histiocyte Society. J Allergy Clin Immunol Pract 6(5):1508\u20131517. https:\/\/doi.org\/10.1016\/j.jaip.2018.05.031[publishedOnlineFirst:2018\/09\/12]","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"6184_CR17","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/pbc.21039","volume":"48","author":"JI Henter","year":"2007","unstructured":"Henter JI, Horne A, Arico M et al (2007) HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48(2):124\u2013131. https:\/\/doi.org\/10.1002\/pbc.21039","journal-title":"Pediatr Blood Cancer"},{"issue":"17","key":"6184_CR18","doi-asserted-by":"publisher","first-page":"4577","DOI":"10.1182\/blood-2011-06-356261[publishedOnlineFirst:2011\/09\/09]","volume":"118","author":"H Trottestam","year":"2011","unstructured":"Trottestam H, Horne A, Arico M et al (2011) Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood 118(17):4577\u20134584. https:\/\/doi.org\/10.1182\/blood-2011-06-356261[publishedOnlineFirst:2011\/09\/09]","journal-title":"Blood"},{"issue":"23","key":"6184_CR19","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1182\/blood.2018894618[publishedOnlineFirst:2019\/04\/18]","volume":"133","author":"P La Rosee","year":"2019","unstructured":"La Rosee P, Horne A, Hines M et al (2019) Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 133(23):2465\u20132477. https:\/\/doi.org\/10.1182\/blood.2018894618[publishedOnlineFirst:2019\/04\/18]","journal-title":"Blood"},{"issue":"7","key":"6184_CR20","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/00043426-200210000-00011","volume":"24","author":"L Sung","year":"2002","unstructured":"Sung L, King SM, Carcao M et al (2002) Adverse outcomes in primary hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol 24(7):550\u2013554","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"6184_CR21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/MPH.0b013e3181923cb4","volume":"31","author":"AA Gupta","year":"2009","unstructured":"Gupta AA, Tyrrell P, Valani R et al (2009) Experience with hemophagocytic lymphohistiocytosis\/macrophage activation syndrome at a single institution. J Pediatr Hematol Oncol 31(2):81\u201384. https:\/\/doi.org\/10.1097\/MPH.0b013e3181923cb4","journal-title":"J Pediatr Hematol Oncol"},{"issue":"19","key":"6184_CR22","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1911326[publishedOnlineFirst:2020\/05\/07]","volume":"382","author":"F Locatelli","year":"2020","unstructured":"Locatelli F, Jordan MB, Allen C et al (2020) Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N Engl J Med 382(19):1811\u20131822. https:\/\/doi.org\/10.1056\/NEJMoa1911326[publishedOnlineFirst:2020\/05\/07]","journal-title":"N Engl J Med"},{"issue":"7","key":"6184_CR23","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1182\/blood-2002-01-0172[publishedOnlineFirst:2002\/09\/20]","volume":"100","author":"JI Henter","year":"2002","unstructured":"Henter JI, Samuelsson-Horne A, Arico M et al (2002) Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood 100(7):2367\u20132373. https:\/\/doi.org\/10.1182\/blood-2002-01-0172[publishedOnlineFirst:2002\/09\/20]","journal-title":"Blood"},{"issue":"15","key":"6184_CR24","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.1182\/blood-2011-03-278127[publishedOnlineFirst:2011\/08\/11]","volume":"118","author":"MB Jordan","year":"2011","unstructured":"Jordan MB, Allen CE, Weitzman S et al (2011) How I treat hemophagocytic lymphohistiocytosis. Blood 118(15):4041\u20134052. https:\/\/doi.org\/10.1182\/blood-2011-03-278127[publishedOnlineFirst:2011\/08\/11]","journal-title":"Blood"},{"issue":"3","key":"6184_CR25","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/art.39332","volume":"68","author":"A Ravelli","year":"2016","unstructured":"Ravelli A, Minoia F, Davi S et al (2016) 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism\/American College of Rheumatology\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol 68(3):566\u2013576. https:\/\/doi.org\/10.1002\/art.39332","journal-title":"Arthritis Rheumatol"},{"key":"6184_CR26","doi-asserted-by":"publisher","unstructured":"Filipovich AH (2009) Hemophagocytic lymphohistiocytosis (HLH) and related disorders. Hematology Am Soc Hematol Educ Program 2009:127\u2013131. https:\/\/doi.org\/10.1182\/asheducation-2009.1.127 [published Online First: 2009\/12\/17]","DOI":"10.1182\/asheducation-2009.1.127"},{"issue":"7","key":"6184_CR27","doi-asserted-by":"publisher","first-page":"996","DOI":"10.3899\/jrheum.161286","volume":"44","author":"SS Ahn","year":"2017","unstructured":"Ahn SS, Yoo BW, Jung SM et al (2017) Application of the 2016 EULAR\/ACR\/PRINTO classification criteria for macrophage activation syndrome in patients with adult-onset Still disease. J Rheumatol 44(7):996\u20131003. https:\/\/doi.org\/10.3899\/jrheum.161286","journal-title":"J Rheumatol"},{"key":"6184_CR28","doi-asserted-by":"publisher","unstructured":"Porter R, Berliner N (2016) Diagnosis and treatment of HLH in adults. [Rinsho ketsueki] Japan J Clin Hematol 57(10):2059\u20132063 https:\/\/doi.org\/10.11406\/rinketsu.57.2059 [published Online First: 2016\/11\/01]","DOI":"10.11406\/rinketsu.57.2059"},{"issue":"5","key":"6184_CR29","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.jpeds.2013.06.053","volume":"163","author":"S Chandrakasan","year":"2013","unstructured":"Chandrakasan S, Filipovich AH (2013) Hemophagocytic lymphohistiocytosis: advances in pathophysiology, diagnosis, and treatment. J Pediatr 163(5):1253\u20131259. https:\/\/doi.org\/10.1016\/j.jpeds.2013.06.053","journal-title":"J Pediatr"},{"key":"6184_CR30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2147\/TCRM.S64951","volume":"11","author":"Y Jamilloux","year":"2015","unstructured":"Jamilloux Y, Gerfaud-Valentin M, Henry T et al (2015) Treatment of adult-onset Still\u2019s disease: a review. Ther Clin Risk Manag 11:33\u201343. https:\/\/doi.org\/10.2147\/TCRM.S64951","journal-title":"Ther Clin Risk Manag"},{"issue":"8","key":"6184_CR31","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1007\/s10067-020-04949-0[publishedOnlineFirst:2020\/03\/05]","volume":"39","author":"R Wang","year":"2020","unstructured":"Wang R, Li T, Ye S et al (2020) Macrophage activation syndrome associated with adult-onset Still\u2019s disease: a multicenter retrospective analysis. Clin Rheumatol 39(8):2379\u20132386. https:\/\/doi.org\/10.1007\/s10067-020-04949-0[publishedOnlineFirst:2020\/03\/05]","journal-title":"Clin Rheumatol"},{"issue":"1","key":"6184_CR32","doi-asserted-by":"publisher","first-page":"84","DOI":"10.4049\/jimmunol.1302282[publishedOnlineFirst:2013\/11\/22]","volume":"192","author":"TS Johnson","year":"2014","unstructured":"Johnson TS, Terrell CE, Millen SH et al (2014) Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis. J Immunol 192(1):84\u201391. https:\/\/doi.org\/10.4049\/jimmunol.1302282[publishedOnlineFirst:2013\/11\/22]","journal-title":"J Immunol"},{"key":"6184_CR33","doi-asserted-by":"publisher","unstructured":"Huang W, Wang Y, Wang J, et al (2014) [Clinical characteristics of 192 adult hemophagocytic lymphohistiocytosis]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 35(9):796\u2013801 https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2014.09.003 [published Online First: 2014\/09\/24]","DOI":"10.3760\/cma.j.issn.0253-2727.2014.09.003"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06184-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-022-06184-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06184-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T14:27:44Z","timestamp":1675607264000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-022-06184-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,19]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["6184"],"URL":"https:\/\/doi.org\/10.1007\/s10067-022-06184-1","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,19]]},"assertion":[{"value":"20 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}